B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SCN1A

MOLECULAR TARGET

sodium voltage-gated channel alpha subunit 1

UniProt: P35498NCBI Gene: 632322 compounds

SCN1A (sodium voltage-gated channel alpha subunit 1) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SCN1A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Flunarizine Flunarizine is1.614
2Saxitoxin1.102
3Mianserin0.691
4Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent0.691
5Bupivacaine0.691
6Chlorpheniramine0.691
7Cinnarizine0.691
8Cyproheptadine0.691
9Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of0.691
10Dibucaine0.691
11dilazep0.691
12Etidocaine0.691
13Hydroxyzine0.691
14lidoflazine0.691
15Nortriptyline0.691
16Phenobarbital0.691
17Phentolamine0.691
18Promethazine0.691
19protriptyline0.691
20Quinidine0.691
21Reserpine0.691
22Veratridine0.691

About SCN1A as a Drug Target

SCN1A (sodium voltage-gated channel alpha subunit 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented SCN1A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SCN1A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.